Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020
November 05 2020 - 6:00AM
Business Wire
Omeros Corporation (NASDAQ: OMER) today announced that the
company will issue its third quarter financial results for the
period ended September 30, 2020, on Monday, November 9, 2020, after
the market closes. Omeros management will host a conference call
and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time) to discuss the financial results as well as recent
developments and highlights.
Conference Call Details
To access the live conference call via phone, please dial (844)
831-4029 from the United States and Canada or (920) 663-6278
internationally. The participant passcode is 1738549. Please dial
in approximately 10 minutes prior to the start of the call. A
webcast replay will be available following the call.
To access the live and subsequently archived webcast of the
conference call, go to Omeros’ website at www.omeros.com and select
“Events” under the Investors section of the website. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed
to discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting inflammation, complement-mediated diseases, disorders of
the central nervous system and immune-related diseases, including
cancers. In addition to its commercial product OMIDRIA
(phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros
has multiple late-stage clinical development programs focused on
complement-mediated disorders, including COVID-19, and substance
abuse. A rolling biologics license application for narsoplimab, the
company’s lead MASP-2 inhibitor, in hematopoietic stem cell
transplant-associated thrombotic microangiopathy is being completed
for submission to the U.S. FDA. Omeros also has a diverse group of
preclinical programs including GPR174, a novel target in
immuno-oncology that modulates a new cancer immunity axis recently
discovered by Omeros. Small-molecule inhibitors of GPR174 are part
of Omeros’ proprietary G protein-coupled receptor (GPCR) platform
through which it controls 54 new GPCR drug targets and their
corresponding compounds. The company also exclusively possesses a
novel antibody-generating platform.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201105005378/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations 360.668.3701
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024